Tranexamic acid administration in primary total hip arthroplasty: intravenous combined with topical vs intravenous? A randomized controlled trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004671

Enrollment

Unknown

Registered

2014-09-21

Start date

2014-05-26

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end-stage hip joint disease

Interventions

trial group 1:intravenous (15mg/kg) combined with topical (1000m

trial group 2:intravenous (15mg/kg) use tranexamic acid

control group:intravenous (15mg/kg) use tranexamic acid

Eligibility

Sex/Gender

Male

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: All patients undergoing primary total hip arthroplasty during study period

Exclusion criteria

Exclusion criteria: allergy to tranexamic acid; preoperative hepatic or renal dysfunction; preoperative use of anticoagular medication seven days prior to surgery; history of fibrinolytic disorder or blood dyscrasia; cerebrovascular accident, myocardial infarction, New York heart association class III or IV heart failure, atrial fibrillation, history of deep vein thrombosis or pulmonary embolus, preoperative INR >1.4, aPTT >1.4 x normal, platelets <140000/mm3.

Design outcomes

Primary

Measure	Time frame
hip function evaluation;haemoglobin level;drainage amount;perioperative complications: deep vein thrombosis;	—

Secondary

Measure	Time frame
hospitalization expense;X-ray radiograph;	—

Countries

China

Contacts

Public ContactShen Bin

shenbin_1971@163.com+86 13881878767

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026